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Abstract
RNA polymerase III (Pol-III) transcribes tRNAs and other small RNAs essential for protein synthesis and cell growth.
Pol-III is deregulated during carcinogenesis; however, its role in vivo has not been studied. To address this issue, we
manipulated levels of Brf1, a Pol-III transcription factor that is essential for recruitment of Pol-III holoenzyme at tRNA
genes in vivo. Knockout of Brf1 led to embryonic lethality at blastocyst stage. In contrast, heterozygous Brf1 mice were
viable, fertile and of a normal size. Conditional deletion of Brf1 in gastrointestinal epithelial tissues, intestine, liver and
pancreas, was incompatible with organ homeostasis. Deletion of Brf1 in adult intestine and liver induced apoptosis.
However, Brf1 heterozygosity neither had gross effects in these epithelia nor did it modify tumorigenesis in the intestine
or pancreas. Overexpression of BRF1 rescued the phenotypes of Brf1 deletion in intestine and liver but was unable to
initiate tumorigenesis. Thus, Brf1 and Pol-III activity are absolutely essential for normal homeostasis during
development and in adult epithelia. However, Brf1 overexpression or heterozygosity are unable to modify
tumorigenesis, suggesting a permissive, but not driving role for Brf1 in the development of epithelial cancers of the
pancreas and gut.
Introduction
RNA polymerase III (Pol-III) transcribes tRNAs and
other short non-coding RNAs that are important in protein
production. Pol-III is the largest of the RNA polymerases
containing 17 subunits, all necessary for transcription and
cell viability [1–4]. The recently solved structure of
initiating Pol-III reveals its similarity to Pol-II, and
demonstrates the multitude of interactions required for
transcription initiation [5, 6]. Pol-III holoenzyme is
directed to the majority of its target genes via two Pol-III-
associated transcription factor complexes, TFIIIB and
TFIIIC [7, 8]. TFIIIC recognises sequences in the body of
Pol-III transcribed genes and recruits TFIIIB [4, 8], which
in turn recruits Pol-III in order to commence transcription
[9–12]. Recruitment of TFIIIB is the rate-limiting step in
Pol-III-dependent transcription [9]. TFIIIB is composed
of three proteins BDP1, TBP and BRF1. While TBP is
shared between all three polymerases, BDP1 and BRF1
are exclusively utilized by Pol-III [8]. The BRF1 homo-
logue BRF2 forms a distinct complex with BDP1 and
TBP to promote transcription of type III Pol-III targets
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[13, 14]. The BDP1/TBP/BRF1 complex is required for
type I and II target genes, which accounts for the
majority of Pol-III transcription. Growth related kinases,
oncoproteins and tumor suppressors regulate Pol-III
transcription, assuring appropriate levels of Pol-III tran-
scripts [15, 16]. The majority of these signals are chan-
nelled through BRF1, making it a signal hub at tRNA
genes [17–25].
Pol-III transcription is vital for cellular maintenance and
important for growth and proliferation. For example, Pol-III
transcription is upregulated during cardiomyocyte pro-
liferation and drops during cell differentiation [26, 27]. Pol-
III transcription is essential in organismal homeostasis and
development. In zebrafish, a 60% reduction in Pol-III
activity had a profound effect during larvae development,
especially in the intestine and exocrine pancreas [28].
Moreover, deletion of Brf1 in Drosophila reduced pupa size
and gave rise to smaller adult flies [29, 30].
In mice, deletion of selenocysteine-tRNA causes a pre-
implantation defect [31]. Furthermore homozygous deletion
of La protein, a known positive regulator of Pol-III tran-
scription, blocks embryo development pre-implantation [32,
33]. However, La proteins affect other pathways besides
Pol-III transcription [34]. During mouse embryo develop-
ment the pre-implantation stage is characterised by a burst
of transcription and translation that may be dependent on
Pol-III activity [35, 36].
Pol-III levels positively correlate with cellular transfor-
mation [37–39] and subunits of Pol-III are known to be
overexpressed in tumours [16, 22, 40]. Data also suggest
that cancer cell lines regulate tRNA availability in order to
support cell growth and proliferation [40]. For example,
tRNAiMET, the initiator tRNA, is overexpressed drives
cancer progression [40, 41]. Since Brf1 is essential for
recruitment of Pol-III holoenzyme at tRNA genes it is
unsurprising that knockdown of BRF1 protects against
transformation in transformed cell lines [42]. Moreover,
BRF1 protein may serve as a biomarker in hepatocellular
carcinoma where levels of BRF1 were higher and correlated
with poor survival [43]. Importantly, elevated levels of
tRNAiMET drive tumor cell migration without affecting
proliferation [44, 45]. Taken together these data suggest that
the link between Pol-III function and tumorigenesis is not
necessarily direct and requires further investigation.
To address this we modulated Brf1 levels in mice finding
that genetic ablation of Brf1 stops embryonic development
and is incompatible with adult organ homeostasis. Adult
epithelial cells lacking Brf1 show a reduction in tRNAs and
polysomes, followed by p53 induction and apoptosis. In
contrast, heterozygous loss or overexpression of Brf1 does
not alter homeostasis or tumorigenesis. Taken together
these studies suggest a crucial function for Pol-III activity in
both normal and cancer cells, but does not limit tumour
initiation in the intestine and pancreas.
Results
BRF1 deletion is embryonically lethal
To assess the effect of Brf1 deletion in mice exon 3 was
flanked by two LoxP sites creating a conditional Brf1 allele
(Fig. 1a and S Fig. 1). We generated Brf1 heterozygous
animals (Brf1+/−) by crossing mice containing the condi-
tional Brf1 allele (Brf1fl/+) to deleter-Cre mice (S Fig. 2A)
[46]. Brf1+/− mice, heterozygous for Brf1, were comparable
to wild-type controls in terms of body weight and other
visible phenotypes (S Fig. 2B). No Brf1−/− mice were
obtained upon inter-breeding of Brf1+/− mice, suggesting
that Brf1 deletion is embryonically lethal (Fig. 1b). Fur-
thermore, the ratio of heterozygous to wild-type mice was
significantly skewed from an expected Mendelian ratio of
1:2:1 (Chi-square test, p < 1 × 10−4 for mice at 4 weeks),
suggesting an effect of Brf1 heterozygosity during
development.
BRF1 is essential for blastocyst formation
Embryos undergo three rounds of cell division to reach the
“8-cell” stage, then progresses to morulae and undergo
further division and differentiation to give rise to blastocysts
that implants into the uterine wall. During implantation a
dramatic increase in growth and energy usage is observed
[47]. Harvesting embryos at either 3.5 days post coitus
(dpc) or 13.5dpc revealed the presence of Brf1−/− embryos
only at 3.5dpc, suggesting that Brf1 is essential for embryo
development after 3.5dpc (Fig. 1b). At 3.5dpc, >90% of
Brf1+/+ mouse embryos were at the blastocyst stage,
compared to only 70% of Brf1+/− embryos and none of the
Brf1−/− embryos (Fig. 1c). These results suggest an essen-
tial role for Brf1 during blastocyst formation at 3.5dpc. It is
worth noting that Brf1 heterozygosity may repress the
passage from morulae to blastocyst (p < 1 × 10−4, n= 11),
in line with reduced Brf1 perturbing early embryonic
development.
To distinguish if loss of Brf1 causes a delay or a com-
plete block of the passage from morulae to blastocyst we
isolated 3.5dpc embryos from Brf1+/− inter-crosses and
cultured them in vitro. After 5 days in culture a considerable
number of embryos hatched and colonised in vitro,
mimicking uterine implantation (Fig. 1d). No Brf1−/− cul-
tured embryos advanced to blastocyst stage, whereas all
Brf1+/+ embryos hatched at 2 or 3 days after plating (5.5dpc
and 6.5dpc). A number of Brf1+/− embryos hatched at later
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time points, underscoring the role of Brf1 during embryo
development (Fig. 1d).
Eight-cell embryos were collected at 2.5dpc and cultured
for 2 days to monitor progression to blastocyst. While wild-
type and Brf1+/− 8-cell embryos became blastocysts within
2 days, none of the 12 Brf1−/− embryos isolated progressed
(Fig. 1e). Taken together these data show that Brf1 is
essential for blastocyst formation and that Brf1 hetero-
zygosity slows progression, which may account for sub-
Mendelian ratios of pups.
BRF1 is essential for liver function
We next assessed the impact of attenuating specific Pol-III
activities in adult mice using AhCre. This Cre recombinase
is under the control of a Cyp1a1 promoter that can be
induced by β-naphthoflavone [48]. Recombination occurs in
hepatocytes and the enterocytes of the small intestine [48],
allowing the comparison of slowly dividing hepatocytes
with highly proliferative intestinal enterocytes and stem
cells.
Fig. 1 Brf1 deletion causes a pre-implantation defect. a Strategy used
to generate the Brf1flox allele. Grey arrowheads are Flip sites used to
excise the puro cassette; black arrowheads are loxP sites inserted
flanking exon 3 of the Brf1 locus. b Table of mice and embryos
generated after crossing Brf1+/− mice (dpc, days post coitus). c Mor-
phology of 3.5dpc embryos captured with a light microscope. Geno-
types are as shown. Percentages depict number of embryos at the
blastocyst stage, characterised by vacuole like presence, or the morulae
stage. d Top panels show pictures of embryos at 3.5dpc when growth
in vitro commenced and after 5 days in culture. Brf1+/+ and Brf1+/−
embryos shown after 5 days have colonised the plate. Bottom panel
shows graphical representation of the time embryos hatch and rupture
the zona pellucida for Brf1+/+ (n= 9) and Brf1+/− (n= 12) embryos.
e Top panels show 2.5dpc embryos in vitro at the start of culture and
after 2 days in culture. The table shows the genotypes of individual
embryos harvested after 2 days in culture
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At 8 days post-induction (dpi) we observed increased
levels of circulating Bilirubin, alkaline phosphatase and
alanine aminotransferase in AhCre Brf1fl/fl mice (Fig. 2a)
consistent with liver injury and dysfunction. Lineage tracing
experiments with the Rosa26LSL-RFP reporter allele showed
that virtually all hepatocytes retained RFP expression
(Fig. 2b). Furthermore, Brf1 mRNA levels were reduced as
visualised by BaseScope and quantified by qPCR (Fig. 2c,
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d). Importantly this resulted in a specific loss of Brf1
function, as tRNAiMET and tRNAILE14 levels were reduced
within 2 days of induction and remained low at 6dpi and
8dpi, whereas expression of the Brf1-independent Pol-III
target U6 was not reduced (Fig. 2d).
Reduced tRNA levels are likely to decrease protein
synthesis. To investigate this we quantified the translation
activity in Brf1 deficient hepatocytes using sucrose density
gradient analysis at 4, 6 and 8dpi. Livers at 4dpi showed a
decrease in polysome loading that decreased further during
the time course (Fig. 3a). Indeed, at 8dpi there are virtually
no polysomes remaining, consistent with a shortage of
tRNAs dramatically decreasing translation rates.
Consistently, Brf1 deletion was detrimental for liver
homeostasis, with morphology notably altered 6 and 8dpi.
Brf1 deficient livers showed high levels of apoptosis,
immune cell infiltration and necrosis (Fig. 3b). Moreover,
Brf1 deficient livers were significantly smaller at day 8
(Fig. 3c). Brf1 deletion resulted in a modest induction of
p53 at 4dpi, which increased further on days 6 and 8
(Fig. 3d). The stress markers p21 and γH2AX were also
increased, but only from 6dpi, with prominent induction at
day 8 (Fig. 3d, S Fig. 3A). Some hepatocytes also stained
for cleaved caspase 3, a feature of apoptosis, and cyto-
plasmic cytokeratin, a feature of collapse (S Fig. 3B).
Importantly, the liver stress phenotype occurs after the
molecular effect of Brf1 deletion on translation seen at
day 4, implicating suppressed translation as the driver of
liver damage.
To remove any confounding effects of extrahepatic
recombination of the Brf1 allele we used a liver tropic
adeno-associated virus construct (AAV8) to deleted Brf1
only in the liver. The rapid and dramatic phenotype of Brf1
deletion was recapitulated in this system, where within
4 days of AAV treatment p53 levels were induced and
within 6 days p21 and cleaved caspase 3 levels were
upregulated in Brf1fl/fl mice (S Fig. 4A). AAV8-CRE
treatment brought upon a liver collapse phenotype in
Brf1fl/fl mice as characterised by increased pan-cytokeratin
staining and circulating levels of bilirubin, alkaline phos-
phatase and alanine aminotransferase (S Fig. 4B). This was
accompanied by reduced liver to body weight in (S Fig. 4C)
and decreased tRNAILE14 but no reduction in U6 RNA
expression (S Fig. 4D).
Importantly, heterozygous deletion of Brf1 using AAV8-
CRE did not result in a reduction of Brf1 protein, despite
efficient loss of the protein following homozygous deletion
(S Fig. 4E). This indicates that heterozygous deletion of the
Brf1 gene is not sufficient to suppress protein expression,
consistent with no effect on Brf1-dependent Pol-III tran-
scription (S Fig. 4D).
BRF1 is essential for gut homeostasis
We next examined intestinal homeostasis in AhCre Brf1+/+,
Brf1fl/+ and Brf1fl/fl mice from 2 to 8dpi. RosaLSL-RFP
reporter recombination was observed within 2dpi in line
with reduced Brf1 mRNA expression (Fig. 4b). Consistent
with reduced Brf1 function there was a reduction in Pol-III
transcript levels by in situ hybridisation against tRNAiMET at
both 2 and 3dpi (Fig. 4a). Therefore, we conclude that from
2dpi, Brf1, and specific Pol-III activity is reduced in the
intestinal epithelium. Histologically we observed smaller,
collapsing crypts and induction of cleaved caspase 3
(Fig. 5a, b). Moreover, at 3dpi, there was an increase in
staining for p53, γH2AX and p21 (Fig. 5c). Therefore,
similar to the liver, loss of Brf1 induces activation of p53,
p21 and γH2AX and apoptosis.
The intestinal epithelium has a remarkable ability to
regenerate, with previous studies showing that deletion of
genes required for viability leading to regeneration of the
intestine from non-recombined cells [48–50]. By 8dpi the
histology of the intestinal epithelium appeared normal. In
contrast to day 2, when Brf1 mRNA expression was
reduced and RFP expression was high, at 8dpi we saw high
Brf1 expression and loss of RFP expression (Fig. 4a). This
strongly suggests that at later time points Brf1 deficient cells
are lost, being replaced by non-recombined Brf1 expressing
cells.
BRF1 overexpression rescues loss of BRF1 but does
not induce proliferation
We next assessed the consequences of increased expression
of Brf1. The liver is slowly proliferative, making this an
ideal organ to assess if Brf1 induction promotes prolifera-
tion and growth. A lox-STOP-lox allele containing human
BRF1 was engineered to express from the Hprt locus upon
Fig. 2 BRF1 down-regulation in the livers of AhCre Brf1fl/fl mice.
a Graphs showing levels of the specified liver enzymes in the blood of
mice of the indicated genotypes. Brf1+/+ mice are a combination of
AhCRE Brf1+/+ and AhCre negative mice, Brf1+/fl mice are AhCRE
Brf1+/fl mice, whilst Brf1fl/fl mice are AhCre Brf1fl/fl mice. P-values are
calculated using a Mann–Whitney non-parametric test and show the
significance between +/+ and fl/fl values. b Immunohistochemistry
for RFP performed on liver sections. Brf1+/+ mice are a combination
of AhCRE Brf1+/+ and AhCre negative mice, whilst Brf1fl/fl mice are
AhCre Brf1fl/fl mice. Day post-induction with β-naphthoflavone is
indicated above the panels. c BaseScope hybridisation showing
expression of Brf1 mRNA in wild-type mice and Brf1fl/fl mice at 2, 6
and 8dpi. d Graphs showing reduction of Brf1 mRNA levels and Pol-
III target levels upon Brf1 loss. Graph on the left depicts levels of Brf1
mRNA measured by qPCR. Reduction in Brf1 mRNA levels is sig-
nificant for each day (p < 0.05). Graph on the right depicts levels of
two tRNAs, tRNAiMET and tRNAILE14, and the U6 RNA. Changes in
tRNA levels are significant on each day (p < 0.05). Mouse genotype
and day post-induction is shown on the x-axis. Values are plotted
relative to WT control for each day shown
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Cre induction (HprtLSL-BRF1). To validate the BRF1 trans-
gene, we assessed whether its expression rescues the phe-
notype of Brf1 loss. We generated AhCre Brf1fl/fl
HprtLSLBRF1 mice (HOM/TG) where, upon induction, both
endogenous copies of Brf1 are deleted and human BRF1 is
expressed. Livers from these mice were harvested 8dpi and
compared with those from AhCre Brf1+/+ (WT) and AhCre
Brf1fl/fl (HOM) mice. Human BRF1 was detected by
immunohistochemistry in the HOM/TG mice, indicating
expression from the transgene (Fig. 6a) and Brf1 mRNA
expression was increased in these mice (S Fig. 5A). Fur-
thermore, the levels of tRNAiMet and tRNAILE14 are also
a)
b)
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higher in the HOM/TG mice compared with HOM mice
(S Fig. 5B) demonstrating that human BRF1 is able to
restore, at least in part, Pol-III function following loss of
endogenous Brf1. Importantly, HOM/TG mice have circu-
lating liver enzyme levels and liver sizes comparable to WT
mice, and no induction of p53 or p21 (Fig. 6a-c). Polysome
analysis also showed that the BRF1 transgene rescued the
translational defects seen with Brf1 deletion (S Fig. 6).
Next, we analysed whether acute overexpression of
BRF1 induces proliferation. No robust phenotype was
observed in terms of proliferation or apoptosis in the liver of
AhCre HprtLSL-BRF1 mice at 8dpi. (S Fig. 7A-C). Moreover,
when HprtLSL-BRF1 mice were crossed to animals expressing
ubiquitous CAAG-CreER to activate BRF1 across the mouse,
no gross phenotypes were observed (data not shown).
BRF1 heterozygosity does not alter tumorigenesis
Next we analysed the impact of Brf1 upon intestinal tumor-
igenesis. Previous work has shown that c-Myc stimulates Brf1
and Pol-III-mediated transcription. C-Myc is a target of the
WNT signalling pathway, and haploinsufficiency for c-Myc
can slow Apc loss-mediated intestinal tumorigenesis [51]. We
therefore crossed Brf1fl/+ mice to AhCre Apcfl/+ mice, which
develop tumours upon loss of the remaining Apc allele.
Cohorts of AhCre Apcfl/+ Brf1+/+ and AhCre Apcfl/+
Brf1fl/+ were aged until they developed signs of intestinal
neoplasia. Heterozygous loss of Brf1 did not alter tumor
development (S FIG 8A) or tumor number or size (S
FIG 8B), suggesting that Brf1 is not limiting for intestinal
tumorigenesis. Importantly, following heterozygous dele-
tion of Brf1 in the liver for 10 days we saw a 50% reduction
in Brf1 mRNA, but no difference in Brf1 protein or
expression Pol-III targets (S Fig. 4). It was not possible to
analyse Brf1 protein expression within intestine due to its
multicellular nature; AhCre driven recombination only
deletes genes in a fraction of the tissue. Nevertheless, we
conclude that heterozygous deletion of Brf1 in the intestine
does not limit tumorigenesis.
We next analysed the role of Brf1 in pancreatic tumour
development where heterozygosity for c-Myc strongly
suppresses pancreatic cancer formation [52]. We crossed
Brf1fl/+ mice to the KPC mouse model (LSL-KrasG12D, LSL-
Trp53R172H with Pdx1-Cre). These KPC mice develop
pancreatic ductal adenocarcinoima with a median incidence
of 4 months [53]. Activation of KRAS and loss of p53
increases Pol-III activity in other tumor settings [24, 54].
We generated and aged cohorts of KPC mice either wild-
type, heterozygous or homozygous for deletion of Brf1
(Fig. 7a). There was no change in survival between KPC
and KPC Brf1fl/+ mice; however, there was a significant
delay in PDAC formation in KPC Brf1fl/fl mice (Fig. 7b)
where survival was extended by 40 days compared to KPC
mice. The pancreatic tumours that developed in KPC Brf1fl/fl
mice were similar in morphology to those of KPC and KPC
Brf1fl/+ mice.
Pdx1-Cre expression is mosaic in the developing pan-
creas. Thus, it is possible that non-recombined cells pre-
ferentially populate the pancreas, as previously observed
[55]. We found that tumours from KPC Brf1fl/fl mice
showed a lack of recombination at the Brf1 locus
(S FIG 10A). Therefore the difference in survival is not due
to any effect of Brf1 on tumorigenesis but rather the time
taken for establishment of Brf1-proficient pancreata.
Consistent with this, Pdx1-Cre Brf1fl/fl were lived for
over 300 days (data not shown). Given the embryonic
lethality upon loss of Brf1 and the apparently normal pan-
creata of Pdx1-Cre Brf1fl/fl mice, we examined if these were
also composed of non-recombined cells. Pdx1-Cre Brf1fl/fl
mice carrying the Rosa26LSL-RFP reporter allele did not show
recombination (S FIG 10B) with no recombination con-
firmed by PCR for the Brf1 locus (S FIG 9). Thus, deletion
of Brf1 in the pancreas is not conducive with its
development.
We therefore examined the impact of BRF1 over-
expression in a longer latency (350 days) pancreatic model:
LSL-KrasG12D/+ Pdx1-Cre (KC), crossing this with the
human HprtLSL-BRF1. We saw no difference in survival
between KC and KC HprtLSL-BRF1 (Fig. 7c). Overexpression
of BRF1 was confirmed and increased tRNAiMET and
tRNAILE14 expression at 6 weeks post induction (Fig. 7d, e).
Together this suggests that Brf1-dependent Pol-III activity
is not limiting for pancreatic tumorigenesis.
Interestingly, overexpression of BRF1 in wild-type livers
did not restore tRNA expression (S Fig. 5) in Brf1fl/fl mice
but did increase tRNA expression in Kras mutant pancreas
Fig. 3 Brf1 is essential for adult mouse liver function. a Polysome
profiles from liver samples of Brf1+/+ mice (Ah-Cre Brf1+/+) har-
vested at day 8 post induction and Brf1fl/fl (Ah-Cre Brf1−/−) mice
harvested at days 4 (n= 2), 6 (n= 3) and 8 (n= 4) post induction as
shown. Brf1+/+ mice are a combination of Ah-CRE Brf1+/+ and mice
without Ah-Cre (n= 3). b H&E stained mouse liver samples. Brf1+/+
mice are a combination of AhCRE Brf1+/+ and AhCre negative mice,
whilst Brf1fl/fl mice are AhCre Brf1fl/fl mice. Day post-induction with β-
naphthoflavone is indicated above the panels. Insets for day 6 and day
8 samples are 400x magnifications to better show tissue morphology.
Arrows in the inserts show immune cell infiltration and collapsing
hepatocytes. c Graph depicting mouse liver weight as a fraction of total
body weight. Genotypes and day post-induction are shown on the x-
axis. Brf1+/+ mice are a combination of AhCRE Brf1+/+ and AhCre
negative mice, whilst Brf1fl/fl mice are AhCre Brf1fl/fl mice. P-values
were calculated using a Mann–Whitney test to compare +/+ and fl/fl
data. Changes at day 2 are not significant. Between 4 and 10 mice were
analysed per genotype per time point. d IHC for p53 or p21, as
indicated, on liver samples from mice harvested at 3, 4, 6 and 8dpi.
Day post-induction with β-naphthoflavone is indicated above the
panels. Brf1+/+ mice are a combination of AhCRE Brf1+/+ and AhCre
negative mice, whilst Brf1fl/fl mice are AhCre Brf1fl/fl mice
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Fig. 4 Loss of recombined cells upon Brf1 deletion in intestinal crypts.
a Immunohistochemistry for RFP on sections of FFPE intestinal tissue.
Brf1+/+mice are a combination of AhCRE Brf1+/+ and AhCre negative
mice, whilst Brf1fl/fl mice are AhCre Brf1fl/fl mice. Day post-induction
with β-naphthoflavone is indicated above the panels. Scale bar in
100 µm. b BaseScope hybridisation for Brf1 mRNA expression in the
intestines of wild-type (induced AhCre negative Brf1fl/fl mice) or
Brf1fl/fl mice at 2 and 8dpi. c In situ hybridisation using a probe against
tRNAiMET. Brf1+/+ mice are a combination of AhCRE Brf1+/+ and
AhCre negative mice, whilst Brf1fl/fl mice are AhCre Brf1fl/fl mice. Day
post-induction with β-naphthoflavone is indicated above the panels
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(Fig. 7d). This may be due to tissue specific differences in
Pol-III regulation or a role for mutant Kras in tRNA tran-
scription. Mutant Ras promotes tRNA synthesis via Brf1 in
Drosophila [56], providing a possible explanation for the
enhanced tRNA transcription in BRF1 over-expressing,
Kras mutant pancreata.
Discussion
Pol-III activity is upregulated in cancer and is often asso-
ciated with oncogenic driver mutations [16, 22, 38]. Despite
this, few studies have addressed whether increased Pol-III
activity overcomes a functional limitation for Pol-III. It is
also unclear whether there is a therapeutic window for
targeting Pol-III. Therefore, we engineered mice to speci-
fically up or downregulate Brf1, in both normal and can-
cerous cells, to address the role of Pol-III in vivo.
We show that BRF1 is essential for organ homeostasis,
but not limiting in selected instances of tumorigenesis.
Constitutive knockout of Brf1 leads to a pre-implantation
defect due to an impaired passage from morulae to blas-
tocyst at 3.5dpc. There is an increase in energy demand
during at this point of embryo development, and the
embryo is large enough to dilute maternal mRNAs [36].
Pol-III activity has been detected as early as the 2 cell
embryo [57]. Increased growth and energy demand
during the passage from morulae to blastocyst, coupled
with a possible dilution of maternal Brf1 message, makes
Brf1 essential at 3.5dpc. Development was the only
Wild-
type 
Brf1fl/fl 
p53 γH2AX p21 Cleaved caspase 3 
a) b)
c)
Fig. 5 Brf1 is essential in mouse gut homeostasis. a H&E stained
sections of mouse intestinal tissue. Brf1+/+ mice are a combination of
AhCRE Brf1+/+ and AhCre negative mice, whilst Brf1fl/fl mice are
AhCre Brf1fl/fl mice. Day post-induction with β-naphthoflavone is
indicated above the panels. Insets of day 3 samples are 400x magni-
fication to better show tissue morphology. Arrows in the insets show
immune cell infiltration and cells undergoing apoptosis. b Top graph
shows quantification of cleaved caspase 3 counts. Genotypes are
shown on the x-axis and counts per 25 full crypts are shown on the
y-axis. Bottom graph shows quantification of apoptotic figures. Gen-
otypes are shown on the x-axis and apoptotic figure counts per 25 full
crypts are shown on the y-axis. P-values calculated for a Mann–
Whitney non-parametric test are shown. Four mice were used for each
genotype. c IHC on sections of intestine from mice harvested 3dpi
using the antibodies indicated. Brf1+/+ mice are a combination of
AhCRE Brf1+/+ and AhCre negative mice, whilst Brf1fl/fl mice are
AhCre Brf1fl/fl mice
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instance of a phenotype from Brf1 heterozygosity. How-
ever, as Brf1 heterozygous mice were viable and of
normal size there may be compensatory mechanisms
during development.
a)
b) c)
HOMWild-type HOM/TG
Brf1
p53
p21
Fig. 6 Expression of human BRF1 rescues loss of Brf1 liver pheno-
type. a IHC for BRF1, p53 and p21 on liver samples from mice
harvested at day 8 post-induction. Mouse genotypes are indicated
above the panels. WT mice are a combination of AhCre Brf1+/+ mice
and AhCre negative mice, Hom mice are AhCre Brf1fl/fl and Hom TG
mice are AhCre Brf1fl/fl HprtLSLBRF1 mice containing an extra copy of
human BRF1. b Graph depicting mouse liver weight as a fraction of
total body weight of animal harvested 8dpi. Genotypes are indicated
on the x-axis. WT mice are a combination of AhCre Brf1+/+ mice and
AhCre negative mice (n= 11), Hom mice are AhCre Brf1fl/fl (n= 11)
and Hom TG mice are AhCre Brf1fl/fl HprtLSLBRF1 mice containing an
extra copy of human BRF1 (n= 6). P-values are calculated for a non-
parametric Mann–Whitney test. Changes between WT and Hom/TG
mice are not significant whereas changes between Brf1fl/fl and WT
animals are significant (p < 0.05). c Graphs showing levels of the
specified liver enzymes in the blood of mice with the indicated gen-
otypes. WT mice are a combination of AhCre Brf1+/+ mice and AhCre
negative mice (n= 8), Hom mice are AhCre Brf1fl/fl (n= 5) and Hom
TG mice are AhCre Brf1fl/fl HprtLSLBRF1 mice containing an extra copy
of human BRF1 (n= 5). P-values are calculated for a non-parametric
Mann–Whitney test. Changes between WT and Hom/TG mice are not
significant
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Within 3 days of deleting Brf1 in the crypts of the small
intestine we observed an increase in p53, p21, γH2AX
protein and apoptosis. Therefore, in a rapidly dividing
epithelium there is an immediate requirement for Pol-III
activity, and if not present, a p53 response is activated,
likely due to the preceding reduction in the protein
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Fig. 7 Brf1 is essential during
pancreas development.
a Schematic showing the crosses
performed to obtain the
respective cohorts to assess the
effects of Brf1 deletion in a
mouse model of PDAC.
b Kaplan–Meier curves showing
pancreatic tumor-free survival in
KPC Brf1+/+ (n= 32) vs KPC
Brf1fl/+ (n= 26) mice (left
panel) and for KPC Brf1fl/+ (n=
26) vs KPC Brf1fl/fl (n= 8) mice
(right panel). Median survival
for each genotype is indicated.
c Kaplan–Meier survival curves
showing pancreatic tumor-free
survival in KC (Pdx1-Cre
KrasG12D/+, continuous line,
n= 44) vs KC HPRTLSL-BRF1
mice (Pdx1-Cre KrasG12D/+
HPRTLSL-BRF1, disrupted line,
n= 33). d tRNAiMET and
tRNAILE14 expression in
pancreata from KC (Pdx1-Cre
KrasG12D/+) and KC LSLBRF1
mice (Pdx1-Cre KrasG12D/+
HPRTLSL-BRF1) mice at 6 weeks
post induction. N= 3 per
genotype. e Staining for BRF1
in pancreata from KC (Pdx1-Cre
KrasG12D/+) and KC
HPRTLSLBRF1 mice (Pdx1-Cre
KrasG12D/+ HPRTLSL-BRF1) mice
at 6 weeks post induction
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synthesis. It is worth noting that even in times of transla-
tional stress, specific translation can be induced [58]. The
gut is especially sensitised to p53-induced death, as has
been observed following deletion of CHK1 or BRCA2 [59,
60]. We observed rapid repopulation of the intestine with
non-recombined cells, which precluded characterisation of
the impact upon translation. This is a well-known pheno-
type of the intestinal epithelium and is aided by the process
of neutral drift, where a single crypt stem cell can repopu-
late the entire crypt [61, 62].
The liver provided a more tractable system to investigate
the effects of Brf1 loss. Liver epithelial turnover is slower
and effective recombination is possible in a potentially
regenerative epithelium [63, 64]. In Brf1 knockout livers
there was an induction of p53 at day 4, becoming more
prominent at day 6 and day 8, when p21 and γH2AX were
subsequently induced. p53 induction followed the reduction
in polysome associated mRNAs, with a mild reduction at
day 4, which progressed to an almost complete absence of
polysomes by day 8. This ultimately led to liver failure as
evidenced by jaundice, liver architectural disturbance and
clinical deterioration. Given the kinetics of p53 induction
and the polysome profiles, we suggest that reducing Pol-III
activity decreases protein synthesis, which in turn acts as a
“checkpoint” to signal the upregulation of p53. It is also
noted that while the overall rate of protein synthesis falls
after Brf1 deletion we again see a marked induction of p53
and p21. This phenomenon suggests preferential translation
of certain transcripts or a reduced degradation of certain
proteins.
Finally, we show that Brf1 is also essential during pan-
creatic development using Pdx1-Cre. Pdx1 is expressed
from 8.5dpc and plays a role in differentiation of all pan-
creatic lineages. Adult pancreata from Pdx1-Cre Brf1fl/fl
appeared normal but were composed exclusively of non-
recombined cells, arguing for a strong negative selection
against Brf1 deletion.
We hypothesised that Brf1 heterozygous mice would
show suppression of tumour initiation and development.
However, outside a possible impact during embryogen-
esis, we found no effect in homeostasis for three epithelia
(pancreas, intestine and liver), or tumorigenesis for two
epithelia (pancreas and intestine). Given difficulties in
detecting mouse Brf1 protein levels it is possible that
heterozygotes might maintain protein levels similar to
wild-type. Indeed, we have shown this to be the case
following heterozygous deletion in the liver. Conversely,
overexpression of BRF1 did not initiate or promote
tumorigenesis. Therefore, we were unable to find a lim-
iting role for Brf1 activity in cancer despite the large
number of studies showing Pol-III deregulation. Most of
the work investigating Pol-III activity has compared
normal cells to late stage cancer cells. Therefore there has
not been a stage-specific characterisation of the timing of
BRF1 and Pol-III activity upregulation during carcino-
genesis. Thus, it may be that oncogenes such as c-MYC,
activate Pol-III expression during tumor initiation,
mimicking developmental and homeostatic scenarios
where Pol-III activity is required. Consistent with this a
recent study showed a progressive increase in Pol-III
activity in a model of breast cancer initiation and pro-
gression, which correlated with c-MYC activity [65].
However, levels of Pol-III activity are not limiting at
these stages and increasing Pol-III activity per se in the
absence of an oncogenic event is insufficient to drive
proliferation and growth. This differs to the Drosophila
scenario, where BRF1 is required for normal pupa
development [29, 30], and may reflect increased
mechanisms to control growth in longer lived mammals.
Indeed, the oncogenic potential of BRF1 has recently
been questioned with loss-of-function mutations in BRF1
potentially actually responsible for some heritable color-
ectal cancers [66]. Similarly, high BRF1 expression is a
favourable prognostic marker in breast cancer [67].
Finally, it is possible that increased Pol-III activity in
cancer may be important beyond proliferation and growth.
Most work comparing normal and cancer cells involves late
stage aggressive tumor cells. Thus, Pol-III activity may be
important in invasion, migration and angiogenesis. Indeed,
two recent reports show that Pol-III could be involved in
tumour cell migration and metastasis [44, 45]. It is inter-
esting to note that small molecules targeting Pol-I can
specifically target cancer cells while sparing normal coun-
terparts [68]. Approaches to reduce BRF1 beyond hetero-
zygosity might be required to reveal a limiting function and
be tolerated by normal cells.
In summary, we have revealed a vital role for BRF1 in
development and homeostasis. However, we found little
evidence for a role for Brf1 as a driver of cancer as tumor
and normal cells appear equally reliant on its fundamental
activity. Moreover, Pol-III activity alone is not sufficient to
transform cells or drive proliferative or growth phenotypes
in the epithelia studied.
Materials and methods
Genetically modified mice and animal care
Animals were kept in conventional animal facilities and
experiments were carried out in compliance with U.K.
Home Office guidelines (ASPA 1986 & EU Directive
2010). Mice were genotyped by Transnetyx INC. (Cordova,
Tennessee). Brf1fl/+ heterozygous mice were crossed to
Deleter-Cre recombinase [46] to excise exon 3 and generate
the knockout allele. The Brf1fl/+ and HPRTLSL-BRF1 mice
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were also crossed with the Pdx1-Cre and Ah-Cre mouse
strains previously described [48, 69]. To induce recombi-
nation in the Ah-Cre mice three intraperitoneal injections of
β-naphthoflavone (80 mg/kg) were given at 4 h intervals.
For AAV induction, mice were injected with virus particles
2 × 1011 genetic copies (GC)/mouse of either AAV8.TBG.
Cre.Rbg (UPenn Vector Core, #: AV-8-PV1091) vector or
AAV8.TBG.PI.null.bGH (control virus) (UPenn Vector
Core, #: AV-8-PV0148) via tail vein in 100 µl PBS as
previously described [70].
Generating Brf1 flox mice
Mice carrying the Brf1 flox allele were generated by
Taconic Artemis (Cologne, Germany) according to their
standard procedures.
Generating Brf1 TG mice
Conditional BRF1 expressing mice were generated by tar-
geting a human BRF1 cDNA under the Cre-dependent
control of a CAAG promoter to the expression-permissive
HPRT locus [71]. The targeting vector was generated
essentially as described by [72] but with a cDNA
encoding the full length human BRF1 protein cloned
downstream of the lox-stop-lox. The vector was linearised
and electroporated into Hprt-deficient HM1 ES cells, cul-
tured on a DR4 mouse embryonic fibroblast feeder layer
[73, 74].
Homologous recombinants were selected in medium
containing HAT supplement (Sigma). Correct targeting
of the vector to the Hprt locus on both the 5′, and 3′
sides was confirmed using PCR on genomic DNA. Geno-
typing was performed by PCR using Expand Long Tem-
plate (Roche) according to the manufacturer’s
recommendations. Primers used for genotyping targeted ES
cells were 5′: GTTGCTGAGGCAAAAATAGTGTAAT
and CCATTTACCGTAAGTTATGTAACGC and 3′:
CTACCTAGTGAGCCTGCAAACTG and ATGTAA
GTGCTAGGAATTGAACCTG.
Following identification of correctly targeted clones,
derived by injection of targeted mESC into C57BL/6 J
blastocysts according to standard protocols [75]. Germline
transmission was identified by coat colour and transmission
of the transgene confirmed by PCR.
In situ hybridisation
Single strand probes labelled with digoxigenin were gen-
erated from a linearised tRNAiMET gene using DIG RNA
labelling kit (Roche) according to the manufacturer’s spe-
cifications. RNA dot blot analysis was used to normalise the
sense and antisense riboprobes. Hybridization was carried
out in a sealed, humidified container at 65 °C for 24 h with
0.5 ug/ml riboprobe and 50 ug/ml yeast tRNA in 50%
deionised formamide, 5X SSC (pH 4.5), 2% blocking
powder (Roche), 0.5% CHAPS, 1x Denhardt’s solution
(Sigma), 10% Dextran sulphate, 1 μg/μL salmon sperm
DNA (Sigma) and 5 mM EDTA. After hybridization, sec-
tions were rinsed once in 2X SSC (pH 4.5) followed by 3
washes of 20 min at 65 °C in 2X SSC/50% formamide.
Sections were then rinsed 5 times in TBS and blocked for 1
h in 0.5% blocking powder (Roche) in TBS. Signal was
detected using DIG Nucleic Acid Detection Kit (Roche)
according to the manufacturer’s specifications. BaseScope
analysis was carried out according to the manufacturer’s
instructions (ACD Bio) using a probe designed to target
bases 548-633 of mouse Brf1.
Immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin for no
longer than 24 h before being processed into paraffin blocks
according to standard protocols. For harvesting of the
intestine samples, small intestines removed and flushed with
water. The first 5 cm of intestine were divided into 1-cm
lengths, bundled using surgical tape, and then fixed in 4%
formaldehyde at 4 °C for no more than 24 h before pro-
cessing. Tissue sections (5 µm) were either stained using
haematoxylin and eosin (H&E), for histological analysis, or
were used for immunohistochemistry (IHC) using standard
methods. Antibodies used for IHC are in Supplemental
Table 2 together with the appropriate dilutions for use. For
each antibody, staining was performed on at least three mice
of each genotype. Representative images are shown for each
staining.
Crypt size and apoptosis assay
Apoptosis and crypt size were scored from H&E stained
sections as previously described [76]. For each analysis, 25
full crypts or 50 half crypts were scored from at least three
mice of each genotype.
Harvesting and genotyping 2.5dpc and 3.5dpc
embryos
Embryos at 8-cell and blastocyst stage were collected
by dissecting and flushing oviducts with M2 medium
(M7167, Sigma–Aldrich) as described [75]. At 3.5dpc
embryos were genotyped via conventional PCR using a
combination of oligo1, oligo 2 and oligo 3 primers,
sequences shown in Supplemental Table 2. Embryos wer-
e transferred directly in the PCR mixture and loaded into
Bio-Rad DNA Engine DYAD Thermal Cycler with
the following cycling parameters 95 °C 10 min, 30 cycles of
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95 °C 30 s, 60 °C 30 s, 72 °C 30 s and 72 °C 10 min.
PCR products were separated and visualised on an agarose
gel.
In order to carry out the in vitro growth assay each of the
3.5dpc embryos was grown in a separate well of a gelatine-
coated 96-well plate in DMEM media supplemented with
15% Fetal Calf Serum and non-essential amino acids. Pic-
tures of each embryo were taken each day for 5 days using
an Olympus CKX41 light microscope with a Qimageing
Fast 1394 camera and QCapture Pro visualisation program.
After 5 days the embryos were trypsinised off the 96-well
plate and genotyped via conventional PCR described above.
2.5dpc embryos were pooled together and grown in vitro
using M2 medium for 2 days. At the end of the two days
each embryo was separated and genotyped using conven-
tional PCR.
Immunoblotting
Western Blot analysis was performed as described pre-
viously with antibody A301-228A (Bethyl) against BRF1
[17].
PCR and gel electrophoresis
PCR was conducted using TAQ polymerase from Invitro-
gen (1034020) as per manufacturer’s instructions. DNA for
reactions was isolated from pancreatic tumours using the
QiaAmp DNA Blood Mini Kit (Qiagen) as per manu-
facturer’s instructions. 0.1 ng of DNA was used in each
reaction together with a combination of 0.5 mM oligo1 and
either oligo 2 or oligo 3 primers, as per figure legend, and
0.5 mM β-actin primers as control. A Bio-Rad DNA Engine
DYAD Thermal Cycler was used with the following cycling
parameters 95 °C 10 min, 25 cycles of 95 °C 30 s, 60 °C
30 s, 72 °C 30 s and 72 °C 10 min. Samples were loaded in a
polyacrylamide gel and visualised with Sybr Safe as per
manufacturer’s instructions using a Gene Genius Bioima-
ging system with a Syngene GeneSnap visualisation
program.
Quantitative real-time PCR
Quantitative real time PCR was performed using PerfeCTa
SYBR Green FastMix (Quanta BioSciences) according to
the manufacturer’s protocol. Analysis was performed on the
C1000 Thermocycler CFX96 Real Time System (Bio-Rad).
Relative quantification was determined from a standard
curve using the Bio-Rad CFXManager software (Version
1.5.534.011). Primers used are described in Supplemental
Table 1. For each reaction 0.5 mM of forward and reverse
primer mixture was used. Three step PCR cycling para-
meters were used in all reactions as follows 95 °C for
15 min, 35 cycles of 95 °C for 10 s, 60 °C 10 s and 72 °C for
10 s followed by a melting curve.
Polysome profiling
To generate tissue for polysomal profile analysis, the whole
liver of the mouse was perfused with 0.1 mg/ml cyclohex-
imide (Sigma) in PBS and incubated with 0.1 mg/ml
cycloheximide in HBSS (Gibco) with 10 mM EDTA for
5 min at 37 °C. Livers were cut into small pieces and used
for downstream analysis.
Liver pieces were lysed in ice cold 300 mM NaCl,
15 mM MgCl2, 15 mM Tris (pH 7.5) containing 500 units/
ml RNAsin, 1 mg/ml heparin sulphate and 0.1 mg/ml
cycloheximide supplemented with 0.1% (v/v) Triton X-100.
Post-nuclear lysates were layered on ∼10 ml 10–50% (w/v)
sucrose gradients of the same buffer omitting Triton X-100.
Gradients were centrifuged at 38,000 rpm for 3 h at 4 °C in
a SW40Ti rotor (Beckman Coulter) and separated through a
live OD254nm UV spectrometer (Isco).
Blood analysis
Blood was collected via heart puncture immediately upon
euthanizing the animal. Blood samples were processed for a
full liver profile using an Olympus Au640 (Beckman
Coulter) as per manufacturer instructions.
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